Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient

### Chinese Hospital’s CAR-T Therapy Saves the Life of a Ph+ Acute Lymphoblastic Leukemia Patient | Successful Case from The First Affiliated Hospital of Chongqing Medical University

CAR-T Therapy

On November 7, 2023, China’s first CAR-T product for treating adult leukemia, Yuan Ruida (Inaticabtagene Autoleucel Injection), was officially approved for market release. This marks a significant breakthrough in the field of leukemia cellular immunotherapy in China. Recently, The First Affiliated Hospital of Chongqing Medical University successfully treated a young patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (B-ALL), demonstrating the remarkable efficacy of this innovative therapy.

**Successful Case**

The patient, a 20-year-old female, was diagnosed with Ph+ B-ALL in early 2021. Despite undergoing tyrosine kinase inhibitors (TKI) combined with chemotherapy and hematopoietic stem cell transplantation (HSCT), her disease relapsed multiple times. Finally, she tried CAR-T therapy. On February 23, 2024, the patient received a transfusion of Inaticabtagene Autoleucel Injection. Just one month after the transfusion, she achieved complete remission (CR) and minimal residual disease (MRD) negativity. Currently, the patient is recovering well and is about to return to school.

**Professional Care from the Medical Team**

Throughout the treatment, the expert team at The First Affiliated Hospital of Chongqing Medical University demonstrated exceptional medical skills and meticulous care. Professor Li noted that after multiple treatment failures, the patient chose the innovative therapy of Inaticabtagene Autoleucel Injection, which ultimately yielded gratifying results. During the CAR-T transfusion, the medical team closely monitored the patient’s condition, ensuring the safety and effectiveness of the treatment. The patient’s positive attitude and family support also laid the foundation for successful treatment.

**Support from Commercial Insurance**

This treatment not only relied on advanced medical technology but also benefited from the support of the patient’s family’s commercial insurance. During the treatment, the patient’s family actively applied for commercial insurance claims and successfully obtained full compensation, significantly reducing the financial burden. The support from commercial insurance increased the accessibility of the treatment, providing solid backing for the patient’s recovery.

**Future Prospects**

The approval of Inaticabtagene Autoleucel Injection has brought new hope to B-ALL patients, especially young ones. The excellent efficacy and safety of CAR-T therapy will significantly improve their quality of life. With more successful cases emerging, CAR-T therapy is expected to become the new standard for B-ALL treatment.

The successful case at The First Affiliated Hospital of Chongqing Medical University not only showcases the immense potential of Inaticabtagene Autoleucel Injection in treating leukemia but also provides valuable experience and reference for future clinical applications. The patient’s recovery journey is inspiring, symbolizing not only physical recovery but also a rebirth of the spirit.

**Conclusion**

The successful application of CAR-T therapy has shown leukemia patients a light of recovery. The professional team at The First Affiliated Hospital of Chongqing Medical University will continue to promote this innovative therapy, bringing hope and new life to more patients. With the advancement of medical technology and the support of commercial insurance, the future of patients will be even brighter.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com

#CARTherapy #LeukemiaTreatment #InnovativeMedicine #ChongqingMedicalUniversity #MedicalBreakthrough #NewLife #CommercialInsurance #PatientRecovery #CancerTreatment #MedicalTechnology #PatientStory #MedicalAdvancement #HopeAndHealing #ChineseHealthcare #CARTTreatment #PhALL #HealthyFuture